The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

Nitin Kapoor^#^{1

2}, Sanjay Kalra^#³, Wael Al Mahmeed⁴, Khalid Al-Rasadi⁵, Kamila Al-Alawi⁶, Maciej Banach^{7

8

9}, Yajnavalka Banerjee¹⁰, Antonio Ceriello¹¹, Mustafa Cesur¹², Francesco Cosentino¹³, Alberto Firenze¹⁴, Massimo Galia¹⁵, Su-Yen Goh¹⁶, Andrej Janez¹⁷, Peter Kempler¹⁸, Nader Lessan¹⁹, Paulo Lotufo²⁰, Nikolaos Papanas²¹, Ali A Rizvi²², Amirhossein Sahebkar^{23

24

25}, Raul D Santos^{26

27}, Anca Pantea Stoian²⁸, Peter P Toth^#²⁹, Vijay Viswanathan³⁰, Manfredi Rizzo^#³¹; CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO)

Affiliations

¹ Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India.
² Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
³ Department of Endocrinology, Bharti Hospital, B.R.I.D.E., Karnal, 132001, India. brideknl@gmail.com.
⁴ Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
⁵ Medical Research Center, Sultan Qaboos University, Muscat, Oman.
⁶ Department of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman.
⁷ Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland.
⁸ Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
⁹ Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
¹⁰ Department of Biochemistry, Mohammed Bin Rashid University, Dubai, United Arab Emirates.
¹¹ IRCCS MultiMedica, Milan, Italy.
¹² Clinic of Endocrinology, Ankara Güven Hospital, Ankara, Turkey.
¹³ Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Stockholm, Sweden.
¹⁴ Unit of Research and International Cooperation, University Hospital of Palermo, Palermo, Italy.
¹⁵ Department of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Palermo, Italy.
¹⁶ Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
¹⁷ Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.
¹⁸ Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
¹⁹ The Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
²⁰ Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo, São Paulo, Brazil.
²¹ Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
²² Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
²³ Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
²⁴ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
²⁵ Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
²⁶ Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.
²⁷ Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
²⁸ Faculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania.
²⁹ Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³⁰ Diabetes Research Centre, Chennai, India.
³¹ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Palermo, Italy.

^# Contributed equally.

PMID: 36030317
PMCID: PMC9419639
DOI: 10.1007/s13300-022-01311-2

Review

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

Nitin Kapoor et al. Diabetes Ther. 2022 Oct.

. 2022 Oct;13(10):1723-1736.

doi: 10.1007/s13300-022-01311-2. Epub 2022 Aug 27.

Authors

Affiliations

¹ Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India.
² Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
³ Department of Endocrinology, Bharti Hospital, B.R.I.D.E., Karnal, 132001, India. brideknl@gmail.com.
⁴ Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
⁵ Medical Research Center, Sultan Qaboos University, Muscat, Oman.
⁶ Department of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman.
⁷ Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland.
⁸ Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
⁹ Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
¹⁰ Department of Biochemistry, Mohammed Bin Rashid University, Dubai, United Arab Emirates.
¹¹ IRCCS MultiMedica, Milan, Italy.
¹² Clinic of Endocrinology, Ankara Güven Hospital, Ankara, Turkey.
¹³ Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Stockholm, Sweden.
¹⁴ Unit of Research and International Cooperation, University Hospital of Palermo, Palermo, Italy.
¹⁵ Department of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Palermo, Italy.
¹⁶ Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
¹⁷ Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.
¹⁸ Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
¹⁹ The Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
²⁰ Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo, São Paulo, Brazil.
²¹ Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
²² Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
²³ Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
²⁴ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
²⁵ Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
²⁶ Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.
²⁷ Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
²⁸ Faculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania.
²⁹ Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³⁰ Diabetes Research Centre, Chennai, India.
³¹ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Palermo, Italy.

^# Contributed equally.

PMID: 36030317
PMCID: PMC9419639
DOI: 10.1007/s13300-022-01311-2

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been shown to disrupt many organ systems in the human body. Though several medical disorders have been affected by this infection, a few illnesses in addition may also play a role in determining the outcome of COVID-19. Obesity is one such disease which is not only affected by the occurrence of COVID-19 but can also result in a worse clinical outcome of COVID-19 infection. This manuscript summarizes the most recent evidence supporting the bidirectional impact of COVID-19 and obesity. It highlights how the presence of obesity can be detrimental to the outcome of COVID-19 in a given patient because of the mechanical limitations in lung compliance and also by the activation of several thrombo-inflammatory pathways. The sociodemographic changes brought about by the pandemic in turn have facilitated the already increasing prevalence of obesity. This manuscript highlights the importance of recognizing these pathways which may further help in policy changes that facilitate appropriate measures to prevent the further worsening of these two pandemics.

Keywords: Bidirectional impact; COVID-19; Obesity; SARS-CoV-2; Syndemic.

PubMed Disclaimer

Figures

**Fig. 1**
Bidirectional impact of COVID-19 and obesity

See this image and copyright information in PMC

References

1. Kapoor N, Audsley J, Rupali P, et al. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. AIDS. 2019;33(7):1105–1115. doi: 10.1097/QAD.0000000000002161. - DOI - PubMed
1. Sajith KG, Kapoor N, Shetty S, et al. Bone health and impact of tenofovir treatment in men with hepatitis-B related chronic liver disease. J Clin Exp Hepatol. 2018;8(1):23–27. doi: 10.1016/j.jceh.2017.05.009. - DOI - PMC - PubMed
1. Wildman JM, Morris S, Pollard T, Gibson K, Moffatt S. "I wouldn't survive it, as simple as that": syndemic vulnerability among people living with chronic non-communicable disease during the COVID-19 pandemic. SSM Qual Res Health. 2022;2:100032. doi: 10.1016/j.ssmqr.2021.100032. - DOI - PMC - PubMed
1. Sheldon TA, Wright J. Twin epidemics of COVID-19 and non-communicable disease. BMJ. 2020;369:m2618. doi: 10.1136/bmj.m2618. - DOI - PubMed
1. Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(3):870–874. doi: 10.1111/dom.14269. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

Affiliations

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

Authors

Affiliations

Abstract

Figures

References

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous